The microbiota in inflammatory bowel disease with resistance to anti-TNF therapy.

• Project/Area Number: 23590948
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Keio University
• Principal Investigator: OKAZAWA Akira 慶應義塾大学, 医学部, 講師 (50286457)
• Co-Investigator(Kenkyū-buntansha): KANAI Takanori 慶応義塾大学, 医学部, 教授 (40245478)
• Project Period (FY): 2011 – 2013
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
• Keywords: 腸内細菌 / 炎症性腸疾患 / probiotics / 腸内細菌フローラ

Research Abstract

In this study, we analyzed the bacterial composition of fecal samples from inflammatory bowel disease (IBD). We found that the prevalence of one of Clostridia was lower in active ulcerative colitis (UC) than quiescent UC. We stimulated colitic lamina propria mononuclear cells (LPMC) from UC patients and IBD model mice with heat-killed this Clostridia. LPMC incubated with Clostridia produced higher amounts of IL-10 compared to controls. The results suggest Clostridia can suppress intestinal inflammation, probably through IL-10 induction. Therefore FS can be a new strategy of IBD therapy.